vs
BioNexus Gene Lab Corp（BGLC）与GRAIL, Inc.（GRAL）财务数据对比。点击上方公司名可切换其他公司
GRAIL, Inc.的季度营收约是BioNexus Gene Lab Corp的90.1倍（$43.6M vs $483.8K）。BioNexus Gene Lab Corp净利率更高（-214.2% vs -227.5%，领先13.3%）。GRAIL, Inc.同比增速更快（14.0% vs -80.8%）。BioNexus Gene Lab Corp自由现金流更多（$960.1K vs $-63.9M）。过去两年GRAIL, Inc.的营收复合增速更高（27.7% vs -54.9%）
BioNexus Gene Lab Corp是一家生物技术企业，主营分子诊断检测、基因分析及相关生命科学解决方案，服务客户涵盖医疗机构、科研机构及个人用户，核心市场主要覆盖东南亚地区。
GRAIL是2015年成立的美国生物技术企业，总部位于加利福尼亚州门洛帕克，核心业务是研发面向无症状人群的癌症早期筛查检测产品。该公司最初是基因测序企业Illumina旗下的初创子公司，2021年被Illumina全资收购。
BGLC vs GRAL — 直观对比
营收规模更大
GRAL
是对方的90.1倍
$483.8K
营收增速更快
GRAL
高出94.8%
-80.8%
净利率更高
BGLC
高出13.3%
-227.5%
自由现金流更多
BGLC
多$64.8M
$-63.9M
两年增速更快
GRAL
近两年复合增速
-54.9%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $483.8K | $43.6M |
| 净利润 | $-1.0M | $-99.2M |
| 毛利率 | -0.8% | — |
| 营业利润率 | -213.5% | -285.4% |
| 净利率 | -214.2% | -227.5% |
| 营收同比 | -80.8% | 14.0% |
| 净利润同比 | -197.5% | -2.2% |
| 每股收益（稀释后） | — | $-2.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BGLCGRAL
| Q4 25 | $483.8K | $43.6M | ||
| Q3 25 | $2.5M | $36.2M | ||
| Q2 25 | $2.3M | $35.5M | ||
| Q1 25 | $2.1M | $31.8M | ||
| Q4 24 | $2.5M | $38.3M | ||
| Q3 24 | $2.6M | $28.7M | ||
| Q2 24 | $2.0M | $32.0M | ||
| Q1 24 | $2.4M | $26.7M |
净利润BGLCGRAL
| Q4 25 | $-1.0M | $-99.2M | ||
| Q3 25 | $-709.0K | $-89.0M | ||
| Q2 25 | $-616.2K | $-114.0M | ||
| Q1 25 | $-623.3K | $-106.2M | ||
| Q4 24 | $-348.3K | $-97.1M | ||
| Q3 24 | $-1.3M | $-125.7M | ||
| Q2 24 | $199.1K | $-1.6B | ||
| Q1 24 | $-103.8K | $-218.9M |
毛利率BGLCGRAL
| Q4 25 | -0.8% | — | ||
| Q3 25 | 14.8% | — | ||
| Q2 25 | 16.3% | — | ||
| Q1 25 | 16.1% | — | ||
| Q4 24 | 12.3% | — | ||
| Q3 24 | 12.4% | — | ||
| Q2 24 | 14.6% | — | ||
| Q1 24 | 15.3% | — |
营业利润率BGLCGRAL
| Q4 25 | -213.5% | -285.4% | ||
| Q3 25 | -27.6% | -346.2% | ||
| Q2 25 | -27.0% | -446.9% | ||
| Q1 25 | -28.9% | -482.5% | ||
| Q4 24 | -16.5% | -358.0% | ||
| Q3 24 | -50.9% | -640.5% | ||
| Q2 24 | 13.1% | -5133.8% | ||
| Q1 24 | -3.3% | -851.1% |
净利率BGLCGRAL
| Q4 25 | -214.2% | -227.5% | ||
| Q3 25 | -27.9% | -245.8% | ||
| Q2 25 | -27.3% | -320.7% | ||
| Q1 25 | -29.2% | -333.6% | ||
| Q4 24 | -13.8% | -253.8% | ||
| Q3 24 | -51.1% | -438.7% | ||
| Q2 24 | 10.1% | -4958.8% | ||
| Q1 24 | -4.4% | -819.3% |
每股收益（稀释后）BGLCGRAL
| Q4 25 | — | $-2.37 | ||
| Q3 25 | $-0.40 | $-2.46 | ||
| Q2 25 | $-0.34 | $-3.18 | ||
| Q1 25 | $-0.04 | $-3.10 | ||
| Q4 24 | $0.55 | $-1.49 | ||
| Q3 24 | $-0.75 | $-3.94 | ||
| Q2 24 | $0.11 | $-51.06 | ||
| Q1 24 | $-0.01 | $-7.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.5M | $249.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $8.6M | $2.6B |
| 总资产 | $9.3M | $2.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BGLCGRAL
| Q4 25 | $2.5M | $249.7M | ||
| Q3 25 | — | $126.9M | ||
| Q2 25 | — | $127.4M | ||
| Q1 25 | — | $133.9M | ||
| Q4 24 | $2.9M | $214.2M | ||
| Q3 24 | — | $853.6M | ||
| Q2 24 | — | $958.8M | ||
| Q1 24 | — | $199.7M |
股东权益BGLCGRAL
| Q4 25 | $8.6M | $2.6B | ||
| Q3 25 | $6.8M | $2.2B | ||
| Q2 25 | $7.5M | $2.3B | ||
| Q1 25 | $7.8M | $2.4B | ||
| Q4 24 | $8.3M | $2.5B | ||
| Q3 24 | $9.4M | $2.6B | ||
| Q2 24 | $9.5M | $2.7B | ||
| Q1 24 | $9.3M | — |
总资产BGLCGRAL
| Q4 25 | $9.3M | $2.9B | ||
| Q3 25 | $7.6M | $2.6B | ||
| Q2 25 | $9.4M | $2.7B | ||
| Q1 25 | $9.5M | $2.8B | ||
| Q4 24 | $10.4M | $3.0B | ||
| Q3 24 | $11.0M | $3.1B | ||
| Q2 24 | $11.1M | $3.3B | ||
| Q1 24 | $11.2M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $961.1K | $-63.8M |
| 自由现金流经营现金流 - 资本支出 | $960.1K | $-63.9M |
| 自由现金流率自由现金流/营收 | 198.5% | -146.5% |
| 资本支出强度资本支出/营收 | 0.2% | 0.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.9M | $-299.9M |
8季度趋势，按日历期对齐
经营现金流BGLCGRAL
| Q4 25 | $961.1K | $-63.8M | ||
| Q3 25 | $-1.2M | $-63.2M | ||
| Q2 25 | $-737.9K | $-77.0M | ||
| Q1 25 | $-824.1K | $-95.0M | ||
| Q4 24 | $219.2K | — | ||
| Q3 24 | $-1.6M | $-104.6M | ||
| Q2 24 | $-672.3K | $-171.8M | ||
| Q1 24 | $-37.2K | $-207.3M |
自由现金流BGLCGRAL
| Q4 25 | $960.1K | $-63.9M | ||
| Q3 25 | $-1.2M | $-63.6M | ||
| Q2 25 | $-759.4K | $-77.3M | ||
| Q1 25 | $-833.1K | $-95.1M | ||
| Q4 24 | $215.2K | — | ||
| Q3 24 | $-1.8M | $-105.6M | ||
| Q2 24 | $-674.1K | $-173.2M | ||
| Q1 24 | $-59.1K | $-209.8M |
自由现金流率BGLCGRAL
| Q4 25 | 198.5% | -146.5% | ||
| Q3 25 | -48.9% | -175.8% | ||
| Q2 25 | -33.6% | -217.6% | ||
| Q1 25 | -39.0% | -298.6% | ||
| Q4 24 | 8.5% | — | ||
| Q3 24 | -68.5% | -368.4% | ||
| Q2 24 | -34.1% | -541.7% | ||
| Q1 24 | -2.5% | -785.3% |
资本支出强度BGLCGRAL
| Q4 25 | 0.2% | 0.2% | ||
| Q3 25 | 0.2% | 1.1% | ||
| Q2 25 | 0.9% | 1.0% | ||
| Q1 25 | 0.4% | 0.2% | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 7.6% | 3.4% | ||
| Q2 24 | 0.1% | 4.3% | ||
| Q1 24 | 0.9% | 9.5% |
现金转化率BGLCGRAL
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -3.38× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BGLC
暂无分部数据
GRAL
| Screening Revenue | $42.3M | 97% |
| Developmental Services Revenue | $1.3M | 3% |
